Brokerages Expect Agile Therapeutics Inc (AGRX) Will Announce Earnings of -$0.11 Per Share
Analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to report earnings per share of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Agile Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 47.6%. The firm is scheduled to issue its next earnings results on Monday, May 6th.
On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to ($0.34). For the next fiscal year, analysts forecast that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.79) to $0.11. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Agile Therapeutics.
Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04.
Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Agile Therapeutics by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the period. BlackRock Inc. lifted its stake in shares of Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the third quarter valued at about $180,000. Institutional investors own 42.15% of the company’s stock.
AGRX stock opened at $1.61 on Tuesday. Agile Therapeutics has a one year low of $0.23 and a one year high of $3.24. The firm has a market capitalization of $57.41 million, a PE ratio of -2.78 and a beta of 0.36.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Featured Article: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.